Adamis Pharma Recalls Allergy Treatment Symjepi For Potential Manufacturing Defect

  • Adamis Pharmaceuticals Corporation ADMP voluntarily recalls certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg pre-filled single-dose syringes to the consumer level. 
  • The batches are being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. 
  • US WorldMeds (USWM) exclusively markets and distributes Symjepi in the U.S., under license from Adamis. 
  • USWM will handle the entire recall process with Adamis' oversight. 
  • Although not confirmed to be related to the recall, there have been two different customer complaints on three syringes regarding the difficulty of dispensing the product to date. 
  • However, neither US WorldMeds nor Adamis Pharmaceuticals has received or is aware of any adverse events related to this recall.
  • Symjepi is indicated in allergic reactions (Type I) emergency treatment, including anaphylaxis.
  • The products are packaged in 2-count Pre-Filled Single-Dose Syringes per carton.
  • Price Action: ADMP shares are up 0.03% at $0.64 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!